Insider Buying: Mesoblast Limited (ASX:MSB) Insider Acquires 21,428 Shares of Stock

Mesoblast Limited (ASX:MSB) insider Eric Rose acquired 21,428 shares of Mesoblast stock in a transaction dated Tuesday, April 30th. The shares were purchased at an average price of A$6.64 ($4.40) per share, for a total transaction of A$142,324.78 ($94,254.82).

Mesoblast Price Performance

The company has a debt-to-equity ratio of 23.98, a current ratio of 2.71 and a quick ratio of 1.82.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.